

universe.gi.org

Virtual Grand Rounds

MOC QUESTION

If you plan to claim MOC Points for this activity, you will be asked to: Please list specific changes you will make in your practice as a result of the information you received from this activity.

> Include specific strategies or changes that you plan to implement. THESE ANSWERS WILL BE REVIEWED.







Virtual Grand Rounds	Disclosures	universe.gi.org
	Max J. Schmulson, MD Alfasigma Mexico: Advisory Board, Grant Support, Speakers Bureau; Carnot: Speakers Bureau; Ferrer Central America: Grant Support, Speakers Bureau; Gemelli Biotech: Advisory Board, Consultant; Laboratorios Tecnofarma SA Bolivia: Speakers Bureau; Medicamenta Ecuatoriana S.A.: Speakers Bureau; Medix: Speakers Bureau; Megalabs Ecuador: Speakers Bureau; Takeda Mexico: Consultant, Speakers Bureau; Tecnofarma Colombia : Speakers Bureau	
	Sarah K. McGill, MD, MSc, FACG Abbott Laboratories: Stockholder; Align Technologies: Stockholder; Exact Sciences: Research Grant; Finch Pharmaceuticals: Research Grant; Freenome Holdings: Research Grant; Guardant Health: Research Grant; Olympus America: Research Grant; Seattle Genetics: Stockholder	
*A	II of the relevant financial relationships listed for these individuals have be	een mitigated







Post-COVID-19 Disorders of Gut-Brain Interaction (DGBI)/Functional Gastrointestinal Disorders (FGID) Dr. Max Schmulson W.

Professor of Medicine





Laboratory of Liver, Pancreas and Motility (HIPAM)-Unit of Research in Experimental Medicine, Faculty of Medicine-Universidad Nacional Autónoma de México (UNAM). Gastroenterology and Endoscopy, American British Cowdray (ABC) Medical Center. Gastroenterology and Gastrointestinal Motility, Clínica Lomas Altas.

Mexico City


maxjulio@prodigy.net.mx, mschmulson@Gmail.com


11












































Effects of home confinement and social distancing in the general population: Syst. Rev. 26 studies

Anxiety

• Prevalence: 8.3% a 45.1%

Depression

• Prevalence: 14.6% a 46.4%

Most vulnerable ones:

Leung CMC et al. Transl Psychiatry. 2022;12:205.

Females, Younger age, Unemployed, Previous mental health or psychiatric illnesses

Rodríguez-Fernández P et al. Int. J. Environ. Res. Public Health 2021;18:6528.

Mental disorders following COVID 19 and other epidemics: Syst. Rev and Metaanalysis 247 on COVID 19

Probable Anxiety

• Prevalence: 20.7% (IC 95% 12.9-29.7)

Probable Depression


• Prevalence: 18.1% (IC 95% 13.0–23.9)


Psychological Dystress


Prevalence: 13.0% (IC 95% 0–34.1)


Most vulnerable ones:


Female sex, Lower income, Pre-existing medical conditions, Perceived risk of infection, Exhibiting COVID-19-*like* symptoms, Use of social media, Financial stress, Loneliness


































































Impact of the COVID-19 pandemic and lockdown stress on psychological aspects and quality of life in subjects With vs. Without IBS in France

Survey among members (n=794) of the French Association of Patients that Suffer of IBS (*Association des patients souffrant du syndrome de l'intestin irritable* [APSSII]), and family and friends

Consequences	IBS (n=232)	Without IBS (n=72)	р
Anxiety (HAD)	10.6±3.9	6.9±3.6	<0.001
Deppresion (HAD)	7.3±3.85	4.8±3.7	<0.001
HAD Global	17.8±6.5	11.8±6.5	<0.001
Fatigue (0-7)	4.9±1.5	3.6±1.6	<0.001
Sleep disturbances (%)	61.5	53	0.216
New sleep disturbances	12	9.1	0.216
Increase in the sleep disturbances	27.7	13.6	0.038
IBS-QOL (0-100)	47.6±19.9		
QOL in general	77.8±16.8	52.2±27.2	<0.001
		Sabate	JM et al. Med Public Health. 2021 Sep;

Conclusiones
 GI symptoms are very frequent in COVID-19. The main reason for that is the presence of the ACE2 receptor that is required for the attachment of the SARS- CoV-2 spike (S) glycoprotein to the human cells and further released their viral components, and their highest expression within the human body is in the intestinal epithelial cells.
 The inflammation in the gut, increased permeability, dysbiosis, and psychological stress triggered by COVID-19, and the remaining of unviable viral particles, are all potential mechanisms for the development of Post-COVID-19-DGBI.
 The GI sequels of COVID-19 and the development of Post COVID-19 DGBI, have already been reported globally. The variability in their prevalence is due to the differences in the design and methodology of the studies. Therefore, physicians and gastroenterologists need to be aware of these possibilities.
 C. difficile infection needs to be ruled out in patients with newly developed Post COVID-19, especially if they were hospitalized or received antibiotics.
 Also, the history of DGBI predisposes to a higher frequency of GI symptoms during COVID-19, higher psychological distress, lower quality of life, and as a consequence, a higher use of healthcare resources by these patients.

